Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials Unit

ICE Trial

Trial Name:

ICE - A Phase II trial of the addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for the first line treatment of Extensive Stage Small Cell Lung Cancer

Description:

ICE is a trial of the addition of Ipilimumab to Carboplatin and Etoposide chemotherapy for the first line treatment of Extensive Stage Small Cell Lung Cancer. It is a single stage, non-randomised, phase II trial.

Objectives:

Design:

Single stage non-randomised phase II trial

Status:

Completed

Population:

Patients will be recruited so that 40 patients are treated with chemo-immunotherapy. The patients will be recruited from a minimum of 4 and maximum of 10 hospital sites.

Publications:

Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer

Contact Details:

All Trial enquiries should be addressed to ctu@soton.ac.uk

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×